Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.60 |
| ▸ | MAOA | P21397 | 3/20 | 0.60 |
| ▸ | CXCL12 | P48061 | 4/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.49 |
| ▸ | AR | P10275 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL363978 | 0.87 | CXCL12 (0.64) | MAOBMAOACXCL12ABCG2AR | |
| SCHEMBL363719 | 0.80 | LMNA (0.52) | MAOBMAOACXCL12ABCG2KMT2A | |
| SCHEMBL4258093 | 0.79 | NNMT (0.45) | MAOBMAOAMEN1USP2PABPC1 | |
| SCHEMBL4258099 | 0.79 | FLT1 (0.46) | MAOBMAOAMEN1USP2PABPC1 | |
| SCHEMBL4258092 | 0.79 | FLT1 (0.46) | MAOBMAOAMEN1USP2PABPC1 | |
| SCHEMBL363641 | 0.79 | CXCL12 (0.59) | MAOBMAOACXCL12ABCG2 | |
| SCHEMBL364142 | 0.79 | LMNA (0.50) | MAOBMAOACXCL12ABCG2MEN1 | |
| SCHEMBL1390294 | 0.79 | MAOB (0.66) | MAOBMAOAABCG2 | |
| SCHEMBL363768 | 0.76 | LMNA (0.63) | MAOBABCG2MEN1KMT2A | |
| SCHEMBL364871 | 0.75 | MEN1 (0.47) | MAOBMAOACXCL12MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2593426-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | GPBAR1, GPR119, ADRB1 | MAOB 1814/4885MAOA 2715/4885CXCL12 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.